Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Brief Communication: Comparison of Changes in Metabolic Parameters Following Antiretrovial Therapy With Treatment Regimens Containing Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate Publisher Pubmed



Mirmoezzi H1 ; Koochak HE2 ; Dehghan Manshadi SA2 ; Hasannezhad M2, 3 ; Seyedalinaghi S3 ; Semnani K1 ; Abbasian L2, 3 ; Ghaderkhani S2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Infectious Diseases, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tehran, Iran
  3. 3. Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Iranian Institute for reduction of High- Risk Behaviors, Tehran, Iran

Source: AIDS Research and Therapy Published:2025


Abstract

Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naive patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5 kg versus − 1 kg, P-value < 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable. © The Author(s) 2025.